Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
BCL2 overexpression
i
Other names:
BCL2, Bcl-2, PPP1R50, B-cell CLL/lymphoma 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
596
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
BCL2 overexpression
Multiple Myeloma
BCL2 overexpression
Multiple Myeloma
venetoclax
Sensitive: B - Late Trials
venetoclax
Sensitive
:
B
venetoclax
Sensitive: B - Late Trials
venetoclax
Sensitive
:
B
BCL2 overexpression
Diffuse Large B Cell Lymphoma
BCL2 overexpression
Diffuse Large B Cell Lymphoma
zanubrutinib
Sensitive: C3 – Early Trials
zanubrutinib
Sensitive
:
C3
zanubrutinib
Sensitive: C3 – Early Trials
zanubrutinib
Sensitive
:
C3
BCL2 overexpression
Acute Myelogenous Leukemia
BCL2 overexpression
Acute Myelogenous Leukemia
Resistant: C3 – Early Trials
Resistant
:
C3
Resistant: C3 – Early Trials
Resistant
:
C3
BCL2 overexpression
Squamous Cell Carcinoma of Head and Neck
BCL2 overexpression
Squamous Cell Carcinoma of Head and Neck
cisplatin + 5-fluorouracil
Sensitive: C3 – Early Trials
cisplatin + 5-fluorouracil
Sensitive
:
C3
cisplatin + 5-fluorouracil
Sensitive: C3 – Early Trials
cisplatin + 5-fluorouracil
Sensitive
:
C3
BCL2 overexpression
Diffuse Large B Cell Lymphoma
BCL2 overexpression
Diffuse Large B Cell Lymphoma
azacitidine oral
Sensitive: C3 – Early Trials
azacitidine oral
Sensitive
:
C3
azacitidine oral
Sensitive: C3 – Early Trials
azacitidine oral
Sensitive
:
C3
BCL2 overexpression
Diffuse Large B Cell Lymphoma
BCL2 overexpression
Diffuse Large B Cell Lymphoma
Resistant: C3 – Early Trials
Resistant
:
C3
Resistant: C3 – Early Trials
Resistant
:
C3
BCL2 overexpression
Hodgkin Lymphoma
BCL2 overexpression
Hodgkin Lymphoma
Resistant: C3 – Early Trials
Resistant
:
C3
Resistant: C3 – Early Trials
Resistant
:
C3
BCL2 overexpression
Non Small Cell Lung Cancer
BCL2 overexpression
Non Small Cell Lung Cancer
AZD2811
Resistant: D – Preclinical
AZD2811
Resistant
:
D
AZD2811
Resistant: D – Preclinical
AZD2811
Resistant
:
D
BCL2 overexpression
Hodgkin Lymphoma
BCL2 overexpression
Hodgkin Lymphoma
venetoclax
Resistant: D – Preclinical
venetoclax
Resistant
:
D
venetoclax
Resistant: D – Preclinical
venetoclax
Resistant
:
D
BCL2 overexpression
Diffuse Large B Cell Lymphoma
BCL2 overexpression
Diffuse Large B Cell Lymphoma
APG-2575
Sensitive: D – Preclinical
APG-2575
Sensitive
:
D
APG-2575
Sensitive: D – Preclinical
APG-2575
Sensitive
:
D
BCL2 overexpression
Acute Myelogenous Leukemia
BCL2 overexpression
Acute Myelogenous Leukemia
IACS-010759
Resistant: D – Preclinical
IACS-010759
Resistant
:
D
IACS-010759
Resistant: D – Preclinical
IACS-010759
Resistant
:
D
BCL2 overexpression
Multiple Myeloma
BCL2 overexpression
Multiple Myeloma
bortezomib + A-1331852
Sensitive: D – Preclinical
bortezomib + A-1331852
Sensitive
:
D
bortezomib + A-1331852
Sensitive: D – Preclinical
bortezomib + A-1331852
Sensitive
:
D
BCL2 overexpression
Acute Myelogenous Leukemia
BCL2 overexpression
Acute Myelogenous Leukemia
venetoclax + AZD5991
Sensitive: D – Preclinical
venetoclax + AZD5991
Sensitive
:
D
venetoclax + AZD5991
Sensitive: D – Preclinical
venetoclax + AZD5991
Sensitive
:
D
BCL2 overexpression
Lung Cancer
BCL2 overexpression
Lung Cancer
osimertinib
Sensitive: D – Preclinical
osimertinib
Sensitive
:
D
osimertinib
Sensitive: D – Preclinical
osimertinib
Sensitive
:
D
BCL2 overexpression
Lung Cancer
BCL2 overexpression
Lung Cancer
afatinib
Sensitive: D – Preclinical
afatinib
Sensitive
:
D
afatinib
Sensitive: D – Preclinical
afatinib
Sensitive
:
D
BCL2 overexpression
Lung Cancer
BCL2 overexpression
Lung Cancer
venetoclax + gefitinib
Sensitive: D – Preclinical
venetoclax + gefitinib
Sensitive
:
D
venetoclax + gefitinib
Sensitive: D – Preclinical
venetoclax + gefitinib
Sensitive
:
D
BCL2 overexpression
Lung Cancer
BCL2 overexpression
Lung Cancer
gefitinib + ABT 263
Sensitive: D – Preclinical
gefitinib + ABT 263
Sensitive
:
D
gefitinib + ABT 263
Sensitive: D – Preclinical
gefitinib + ABT 263
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login